@article{Sun2021-12Recen-56461,
  year={2021},
  doi={10.1007/s12672-021-00422-9},
  title={Recent advances in cancer immunotherapy},
  number={1},
  volume={12},
  issn={1868-8497},
  journal={Discover Oncology},
  author={Sun, Qiang and Melino, Gerry and Amelio, Ivano and Jiang, Jingting and Wang, Ying and Shi, Yufang},
  note={Article Number: 27}
}

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/56461">
    <dc:contributor>Shi, Yufang</dc:contributor>
    <dcterms:abstract xml:lang="eng">Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.</dcterms:abstract>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/56461"/>
    <dc:creator>Wang, Ying</dc:creator>
    <dcterms:issued>2021-12</dcterms:issued>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/56461/1/Sun_2-15vis3cdtrm3r2.pdf"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Sun, Qiang</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Melino, Gerry</dc:creator>
    <dc:creator>Amelio, Ivano</dc:creator>
    <dc:language>eng</dc:language>
    <dc:creator>Jiang, Jingting</dc:creator>
    <dc:contributor>Jiang, Jingting</dc:contributor>
    <dcterms:title>Recent advances in cancer immunotherapy</dcterms:title>
    <dc:contributor>Melino, Gerry</dc:contributor>
    <dc:contributor>Wang, Ying</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-09T10:31:59Z</dc:date>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/56461/1/Sun_2-15vis3cdtrm3r2.pdf"/>
    <dc:contributor>Amelio, Ivano</dc:contributor>
    <dc:contributor>Sun, Qiang</dc:contributor>
    <dc:creator>Shi, Yufang</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-09T10:31:59Z</dcterms:available>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
  </rdf:Description>
</rdf:RDF>